Bristol-Myers Squibb
BMY
$0.00
-2.32%
Bristol-Myers Squibb Co. is a global biopharmaceutical company that discovers, develops, and markets innovative medicines across key therapeutic areas including oncology, cardiovascular, immunology, and hematology. The company is a market leader in immuno-oncology, anchored by its blockbuster drug Opdivo, and derives a significant portion of its sales from the United States. The current investor narrative is dominated by the company's ongoing strategic pivot, as it navigates the impending patent cliff for major drugs like Eliquis and Revlimid by aggressively growing its newer portfolio, a transition underscored by recent strong quarterly results that highlighted a 12% jump in sales from its newer growth assets. However, this growth story is tempered by competitive pressures, as evidenced by recent news of a rival AI-developed drug demonstrating superior efficacy against one of Bristol-Myers' treatments, highlighting the constant innovation race within the industry.…
BMY
Bristol-Myers Squibb
$0.00
Related headlines
Investment Opinion: Should I buy BMY Today?
Rating: Hold. The core thesis is that BMY is a deeply valued but high-risk turnaround story where the potential reward from successful pipeline execution is balanced by the tangible threat of a significant patent cliff.
Supporting evidence includes a forward P/E of 9.3x implying heavy skepticism, robust FCF of $12.8B supporting the 4.6% yield, and a 12% sales jump in newer assets showing early transition progress. However, these are counterbalanced by mere 1.3% YoY revenue growth, a high D/E ratio of 2.55, and a stock that has underperformed the market by over 10% in the past year. Analyst sentiment is neutral, with recent ratings clustered around 'Hold' and 'Equal-Weight'.
The thesis would upgrade to a Buy if the forward P/E remained below 10x while quarterly revenue growth from newer products sustainably exceeded 15%, signaling the transition is ahead of schedule. It would downgrade to a Sell if sequential total revenue growth turns negative or if the dividend coverage ratio (FCF/Dividend) shows signs of deterioration. Relative to its history and the sector, the stock is undervalued on earnings but fairly valued when accounting for its elevated risk profile.
Sign up to view all
BMY 12-Month Price Forecast
BMY presents a balanced risk/reward profile over the next 12 months. The compelling valuation (forward P/E of 9.3x) and high yield are offset by genuine fundamental headwinds from patent expirations. The base case of a slow, successful grind higher is most probable, but the stock lacks a near-term catalyst for a major re-rating. The stance would turn bullish on evidence of accelerating top-line growth (>5% YoY) while the valuation remains depressed. It would turn bearish if quarterly revenues begin to contract sequentially, signaling the patent cliff impact is more severe than modeled.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Bristol-Myers Squibb's 12-month outlook, with a consensus price target around $0.00 and implied upside of — versus the current price.
Average Target
$0.00
11 analysts
Implied Upside
—
vs. current price
Analyst Count
11
covering this stock
Price Range
$0 - $0
Analyst target range
BMY is covered by 11 analysts, indicating substantial institutional research coverage. The consensus sentiment appears neutral to cautiously optimistic, with recent ratings including 'Hold' from HSBC and Citigroup, 'Equal Weight' from Wells Fargo, and 'Overweight' or 'Buy' from Piper Sandler and Guggenheim. The average target price implied by the estimated revenue and EPS is not explicitly provided, but using the forward P/E and estimated EPS of $4.76, the implied price is approximately $44.10, which would suggest a significant downside from the current $57.13; however, this is a simplistic calculation and the true consensus price target likely differs. The target range for estimated EPS is tight, from $4.66 to $4.86, indicating high conviction in near-term earnings forecasts but less clarity on the appropriate multiple to apply. The high end of the EPS range ($4.86) assumes successful execution on newer drug launches and margin management, while the low end ($4.66) may factor in competitive pressures or slower-than-expected adoption. The recent pattern of institutional ratings shows stability, with no major downgrades or upgrades in the provided data from early 2026, suggesting analysts are in a 'wait-and-see' mode regarding the company's transition through its patent cliff.
Bulls vs Bears: BMY Investment Factors
The evidence currently tilts bearish, as the fundamental risks of patent expirations and stagnant growth are concrete and immediate, while the bullish case relies on future execution of a pipeline that is still in early commercialization. The most important tension in the investment debate is whether the growth from newer assets like Camzyos and Reblozyl can accelerate sufficiently to not just replace, but exceed, the revenue from Eliquis and Revlimid before those patents expire. The stock's deeply discounted forward P/E of 9.3x reflects the market's skepticism, creating a classic value trap versus deep value opportunity scenario.
Bullish
- Deeply Discounted Forward P/E of 9.3x: BMY trades at a forward P/E of 9.27x, a significant discount to its trailing P/E of 15.6x and below typical large-cap pharma averages. This implies the market has priced in substantial earnings recovery, creating a value opportunity if the company's growth pipeline executes successfully.
- Strong Free Cash Flow Supports Dividend: The company generated $12.845 billion in trailing twelve-month free cash flow, providing robust coverage for its dividend which yields 4.6%. This substantial cash generation underpins shareholder returns during the strategic transition.
- Newer Portfolio Growth Accelerating: Recent quarterly results highlighted a 12% jump in sales from newer growth assets like Camzyos and Reblozyl. This demonstrates early success in the pivot away from legacy drugs, a critical component of the investment thesis.
- Defensive Profile with Low Beta of 0.24: BMY's beta of 0.238 indicates it is roughly 76% less volatile than the market, making it a defensive holding. This characteristic provides downside protection during market downturns, appealing to risk-averse investors.
Bearish
- Looming Patent Cliff for Key Drugs: BMY faces significant revenue risk from impending patent expirations for blockbusters Eliquis and Revlimid, which together accounted for over $3.45B and $2.69B in recent sales. The uncertainty of fully replacing this lost revenue is the core bear argument.
- Stagnant Top-Line Revenue Growth: Q4 2025 revenue of $12.502B represents only 1.3% YoY growth, and sequential quarterly data shows a plateauing top line (Q3: $12.222B, Q2: $12.269B). This indicates the newer portfolio growth is not yet offsetting mature product declines.
- High Financial Leverage (D/E of 2.55): A debt-to-equity ratio of 2.55 indicates significant financial leverage. While the high ROE of 38.18% is partly a function of this leverage, it increases financial risk, especially in a higher interest rate environment.
- Intense Competitive & Innovation Pressure: Recent news of Takeda's AI-developed drug showing superior efficacy against a BMY treatment highlights the constant innovation race. This external threat could accelerate market share loss beyond planned patent expirations.
BMY Technical Analysis
BMY's stock has been in a volatile consolidation phase over the past year, with a 1-year price change of +12.70%, significantly underperforming the S&P 500's 22.86% gain, as indicated by a relative strength of -10.16. The current price of $57.13 positions it at approximately 72% of its 52-week range ($42.52 to $62.89), suggesting the stock is in the upper-mid portion of its annual band but remains well off its highs, indicating a recovery from lows but lacking decisive bullish momentum. Recent short-term momentum is mixed, with a 1-month gain of 1.31% contrasting with a 3-month decline of -3.30%, signaling a loss of positive momentum from the early-year rally and a divergence from the broader market's strong 3-month performance of +12.0%. The stock's beta of 0.238 indicates it is significantly less volatile than the overall market, behaving as a defensive holding, though its recent price action shows it has failed to participate in the broader equity rally. Key technical levels are clearly defined, with major resistance at the 52-week high of $62.89 and support at the 52-week low of $42.52; a sustained breakout above $63 could signal a new uptrend, while a breakdown below the recent May lows near $55 would suggest a resumption of the longer-term downtrend. The stock's low beta of 0.238 implies it is roughly 76% less volatile than the SPY, which is a critical consideration for risk management, as it suggests the stock is less sensitive to market swings but may also lack the explosive upside of higher-beta peers.
Beta
0.24
0.24x market volatility
Max Drawdown
-16.0%
Largest decline past year
52-Week Range
$43-$63
Price range past year
Annual Return
+15.3%
Cumulative gain past year
| Period | BMY Return | S&P 500 |
|---|---|---|
| 1m | -7.4% | +0.7% |
| 3m | -6.1% | +15.1% |
| 6m | -0.4% | +9.7% |
| 1y | +15.3% | +25.0% |
| ytd | +1.0% | +9.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BMY Fundamental Analysis
Bristol-Myers Squibb's revenue trajectory shows modest growth with significant quarterly volatility; the most recent Q4 2025 revenue was $12.502 billion, representing a year-over-year growth of 1.3% from the prior-year quarter. However, examining the sequential quarterly data reveals inconsistency, with Q3 2025 revenue at $12.222 billion and Q2 at $12.269 billion, indicating a plateauing top line as the company manages the decline of mature products. The growth is being driven by newer assets, as segment data highlights key contributors like Eliquis ($3.452B), Opdivo ($2.692B), and Orencia ($1.008B), while newer products such as Camzyos ($353M), Reblozyl ($666M), and Opdualag ($350M) are gaining traction but from a smaller base. Profitability metrics are stable but show pressure, with Q4 2025 net income of $1.086 billion and a net margin of 8.7%, a significant improvement from the marginal $72 million profit in Q4 2024 but down from the stronger $2.201 billion in Q3 2025. The gross margin of 67.23% in Q4 2025 is robust and consistent with the trailing twelve-month gross margin of 67.65%, indicating the company maintains strong pricing power and cost control in its product portfolio. The balance sheet and cash flow position is a point of strength and concern; the company generated substantial trailing twelve-month free cash flow of $12.845 billion, providing ample coverage for its dividend, but it carries a high debt-to-equity ratio of 2.55, indicating significant financial leverage. The return on equity is very high at 38.18%, but this is largely a function of the high leverage, while the current ratio of 1.26 suggests adequate short-term liquidity, though not exceptionally strong for a pharmaceutical company of its size.
Quarterly Revenue
$12.5B
2025-12
Revenue YoY Growth
+0.01%
YoY Comparison
Gross Margin
+0.67%
Latest Quarter
Free Cash Flow
$12.8B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BMY Overvalued?
Given BMY's positive net income, the primary valuation metric is the Price-to-Earnings (P/E) ratio. The stock trades at a trailing P/E of 15.61x and a forward P/E of 9.27x, based on estimated EPS of $4.76. The significant discount of the forward multiple implies the market expects a substantial earnings recovery or growth, likely pricing in the successful commercialization of newer drugs and cost management ahead of patent expirations. Compared to sector averages, BMY's valuation presents a mixed picture; its trailing P/E of 15.6x is below the typical large-cap pharma average (often in the high-teens to low-20s), while its Price-to-Sales ratio of 2.28x and EV/Sales of 3.14x also suggest a moderate valuation relative to sales. The stock's Price/Book ratio of 5.96x is elevated, reflecting the market's valuation of its intangible assets (IP and pipeline) over its tangible equity, which is common for R&D-intensive pharma firms. Historically, BMY's current trailing P/E of 15.6x sits below its own 5-year historical average, which has often been above 20x, indicating the stock is trading at a discount to its own historical valuation range. This discount likely reflects investor concerns over the looming patent expirations and the uncertainty surrounding the company's ability to fully replace lost revenue, creating a potential value opportunity if the growth pipeline executes successfully. The forward P/E of 9.3x, if achieved, would represent a historically low earnings multiple for the company, suggesting the market has heavily discounted near-term earnings power.
PE
15.6x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -2x~398x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
10.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are centered on revenue concentration and leverage. Over 70% of sales come from the US, creating geographic concentration risk. The high debt-to-equity ratio of 2.55, coupled with quarterly net income volatility (ranging from $1.086B in Q4 2025 to $2.201B in Q3 2025), indicates financial strain could intensify if the revenue transition falters. Furthermore, the dividend payout ratio of 71.5%, while covered by strong FCF, could come under pressure if cash generation declines post-patent expiry.
Market & Competitive Risks are pronounced. The stock trades at a discount to its own 5-year historical P/E average, suggesting the market has already priced in significant headwinds, but further multiple compression is possible if growth disappoints. The recent news of Takeda's AI-developed drug demonstrating superior efficacy is a tangible example of the relentless competitive and technological disruption in pharma. Additionally, BMY's low beta of 0.238, while defensive, means it may not participate in broad market rallies, as evidenced by its -15.3 relative strength over the past 3 months.
Worst-Case Scenario involves a faster-than-expected erosion of Eliquis/Revlimid sales combined with slower adoption of new drugs and a clinical setback in the pipeline. This could trigger a dividend cut, credit rating downgrades due to high leverage, and a loss of investor confidence. The realistic downside could see the stock re-test its 52-week low of $42.52, representing a potential decline of approximately -26% from the current price of $57.13. The maximum drawdown over the provided period was -15.96%, but a full reversion to the low in a crisis scenario is plausible.
FAQ
The key risks, in order of severity, are: 1) Patent Expiration Risk: Impending loss of exclusivity for mega-blockbusters Eliquis and Revlimid, which currently drive a large portion of revenue and profit. 2) Financial Risk: High debt-to-equity leverage of 2.55, which could strain the balance sheet if earnings decline. 3) Competitive/Innovation Risk: Demonstrated by recent news of an AI-developed rival drug outperforming a BMY treatment; the pace of scientific disruption is relentless. 4) Execution Risk: The newer portfolio (e.g., Camzyos, Reblozyl) must grow rapidly from a small base to offset legacy declines, and any stumble could crater investor confidence.
The 12-month forecast is a range of outcomes centered on a base case. The most likely scenario (60% probability) is a base case with the stock trading between $52 and $58, as the company's transition progresses slowly without major surprises. The bull case (25% probability) targets $63-$68 on successful pipeline execution and a P/E re-rating. The bear case (15% probability) risks a fall to $43-$48 if patent cliff impacts are worse than expected. The key assumption behind the base case is that consensus forward EPS of $4.76 is achieved, supporting the current valuation but not providing a catalyst for significant multiple expansion.
BMY is undervalued based on earnings multiples but fairly valued when adjusting for risk. Its forward P/E of 9.27x is deeply discounted compared to both its own 5-year historical average (often above 20x) and typical large-cap pharma peers. However, this discount rationally reflects the looming patent expirations for Eliquis and Revlimid. The Price/Sales ratio of 2.28x and EV/Sales of 3.14x are moderate for the sector. The valuation implies the market expects minimal earnings growth and has heavily discounted future cash flows, creating a potential opportunity if the company's transition proves more successful than anticipated.
BMY is a suitable buy only for specific investor profiles. For income-focused investors seeking a 4.6% yield with defensive, low-beta characteristics, it presents a compelling case, especially given its robust $12.8B free cash flow. For growth investors, it is not a good buy due to stagnant 1.3% revenue growth and significant transition overhang. The stock's deep forward P/E discount of 9.3x offers value upside, but this is counterbalanced by the tangible risk of its patent cliff. It is a good buy for patient value investors who believe the pipeline will execute, but a poor choice for those seeking near-term capital appreciation or low-risk income.
BMY is unequivocally a long-term investment, with a suggested minimum holding period of 3-5 years. The company's strategic pivot away from its patent cliff is a multi-year story that will unfold through successive quarterly earnings reports and pipeline updates. Its low beta of 0.24 and high dividend yield make it poorly suited for short-term trading, as it lacks the volatility for quick gains and may remain range-bound. Long-term investors can collect the dividend while waiting for the valuation gap to potentially close as the new product portfolio matures. Short-term traders should look elsewhere for more volatile, catalyst-driven names.